Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2020 Nov 17;64(12):e01920-20.
doi: 10.1128/AAC.01920-20. Print 2020 Nov 17.

Captisol and GS-704277, but Not GS-441524, Are Credible Mediators of Remdesivir's Nephrotoxicity

Victoria C Yan  1 , Florian L Muller  2
Affiliations
Comment

Captisol and GS-704277, but Not GS-441524, Are Credible Mediators of Remdesivir's Nephrotoxicity

Victoria C Yan et al. Antimicrob Agents Chemother. .
No abstract available

Keywords: GS-441524; drug metabolism; prodrug; remdesivir; renal clearance.

PubMed Disclaimer

Comment in

Comment on

References

    1. Lê MP, Le Hingrat Q, Jaquet P, Wicky P-H, Bunel V, Massias L, Visseaux B, Messika J, Descamps D, Mal H, Timsit J-F, Peytavin G. 31 August 2020. Removal of remdesivir’s metabolite GS-441524 by hemodialysis in a double lung transplant recipient with COVID-19. Antimicrob Agents Chemother doi:10.1128/AAC.01521-20. - DOI - PMC - PubMed
    1. Stella V, He Q. 2008. Cyclodextrins. Toxicol Pathol 36:30–42. doi:10.1177/0192623307310945. - DOI - PubMed
    1. Hoover RK, Alcorn H, Lawrence L, Paulson SK, Quintas M, Luke DR, Cammarata SK. 2018. Clinical pharmacokinetics of sulfobutylether-β-cyclodextrin in patients with varying degrees of renal impairment. J Clin Pharmacol 58:814–822. doi:10.1002/jcph.1077. - DOI - PMC - PubMed
    1. Beigel JH, Tomashek KM, Dodd LE, Mehta AK, Zingman BS, Kalil AC, Hohmann E, Chu HY, Luetkemeyer A, Kline S, Lopez de Castilla D, Finberg RW, Dierberg K, Tapson V, Hsieh L, Patterson TF, Paredes R, Sweeney DA, Short WR, Touloumi G, Lye DC, Ohmagari N, Oh M, Ruiz-Palacios GM, Benfield T, Fätkenheuer G, Kortepeter MG, Atmar RL, Creech CB, Lundgren J, Babiker AG, Pett S, Neaton JD, Burgess TH, Bonnett T, Green M, Makowski M, Osinusi A, Nayak S, Lane HC, ACTT-1 Study Group Members. 22 May 2020. Remdesivir for the treatment of Covid-19 — preliminary report. N Engl J Med doi:10.1056/NEJMoa2007764. - DOI - PMC - PubMed
    1. Pruijssers AJ, George AS, Schäfer A, Leist SR, Gralinksi LE, Dinnon KH, Yount BL, Agostini ML, Stevens LJ, Chappell JD, Lu X, Hughes TM, Gully K, Martinez DR, Brown AJ, Graham RL, Perry JK, Du Pont V, Pitts J, Ma B, Babusis D, Murakami E, Feng JY, Bilello JP, Porter DP, Cihlar T, Baric RS, Denison MR, Sheahan TP. 2020. Remdesivir inhibits SARS-CoV-2 in human lung cells and chimeric SARS-CoV expressing the SARS-CoV-2 RNA polymerase in mice. Cell Rep 32:107940. doi:10.1016/j.celrep.2020.107940. - DOI - PMC - PubMed